Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1994 Mar;93(3):1288–1292. doi: 10.1172/JCI117084

Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

C E Hollak 1, S van Weely 1, M H van Oers 1, J M Aerts 1
PMCID: PMC294082  PMID: 8132768

Abstract

Gaucher disease (GD; glucosylceramidosis) is caused by a deficient activity of the enzyme glucocerebrosidase (GC). Clinical manifestations are highly variable and cannot be predicted accurately on the basis of the properties of mutant GC. Analysis of secondary abnormalities, such as elevated plasma levels of some hydrolases, may help to increase insight into the complicated pathophysiology of the disease and could also provide useful disease markers. The recent availability of enzyme supplementation therapy for GD increases the need for markers as early predictors of the efficacy of treatment. We report the finding of a very marked increase in chitotrisidase activity in plasma of 30 of 32 symptomatic type 1 GD patients studied: the median activity being > 600 times the median value in plasma of healthy volunteers. In three GC-deficient individuals without clinical symptoms, only slight increases were noted. Chitotriosidase activity was absent in plasma of three control subjects and two patients. During enzyme supplementation therapy, chitotriosidase activity declined dramatically. We conclude that plasma chitotriosidase levels can serve as a new diagnostic hallmark of GD and should prove to be useful in assessing whether clinical manifestations of GD are present and for monitoring the efficacy of therapeutic intervention.

Full text

PDF
1288

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aerts J. M., Donker-Koopman W. E., Koot M., Barranger J. A., Tager J. M., Schram A. W. Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease. Clin Chim Acta. 1986 Jul 30;158(2):155–163. doi: 10.1016/0009-8981(86)90231-7. [DOI] [PubMed] [Google Scholar]
  2. Barton N. W., Brady R. O., Dambrosia J. M., Di Bisceglie A. M., Doppelt S. H., Hill S. C., Mankin H. J., Murray G. J., Parker R. I., Argoff C. E. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991 May 23;324(21):1464–1470. doi: 10.1056/NEJM199105233242104. [DOI] [PubMed] [Google Scholar]
  3. Beutler E., Gelbart T., Kuhl W., Zimran A., West C. Mutations in Jewish patients with Gaucher disease. Blood. 1992 Apr 1;79(7):1662–1666. [PubMed] [Google Scholar]
  4. Beutler E., Kay A., Saven A., Garver P., Thurston D., Dawson A., Rosenbloom B. Enzyme replacement therapy for Gaucher disease. Blood. 1991 Sep 1;78(5):1183–1189. [PubMed] [Google Scholar]
  5. CROCKER A. C., LANDING B. H. Phosphatase studies in Gaucher's disease. Metabolism. 1960 Apr;9:341–362. [PubMed] [Google Scholar]
  6. Chambers J. P., Aquino L., Glew R. H., Lee R. E., McCafferty L. R. Determination of serum acid phosphatase in Gaucher's disease using 4-methylumbelliferyl phosphate. Clin Chim Acta. 1977 Oct 1;80(1):67–77. doi: 10.1016/0009-8981(77)90265-0. [DOI] [PubMed] [Google Scholar]
  7. Daniels L. B., Glew R. H. beta-Glucosidase assays in the diagnosis of Gaucher's disease. Clin Chem. 1982 Apr;28(4 Pt 1):569–577. [PubMed] [Google Scholar]
  8. Den Tandt W. R., Inaba T., Verhamme I., Overdyk B., Brouwer J., Prieur D. Non-identity of human plasma lysozyme and 4-methylumbelliferyl-tetra-N-acetyl-beta-D-chitotetraoside hydrolase. Int J Biochem. 1988;20(7):713–719. doi: 10.1016/0020-711x(88)90167-x. [DOI] [PubMed] [Google Scholar]
  9. Hollak C. E., Aerts J. M., van Oers M. H. Treatment of Gaucher's disease. N Engl J Med. 1993 May 27;328(21):1565–1567. [PubMed] [Google Scholar]
  10. Moss D. W. Changes in enzyme expression related to differentiation and regulatory factors: the acid phosphatase of osteoclasts and other macrophages. Clin Chim Acta. 1992 Jul 31;209(1-2):131–138. doi: 10.1016/0009-8981(92)90344-p. [DOI] [PubMed] [Google Scholar]
  11. Mörsky P. Turbidimetric determination of lysozyme with Micrococcus lysodeikticus cells: reexamination of reaction conditions. Anal Biochem. 1983 Jan;128(1):77–85. doi: 10.1016/0003-2697(83)90347-0. [DOI] [PubMed] [Google Scholar]
  12. Sidransky E., Tsuji S., Martin B. M., Stubblefield B., Ginns E. I. DNA mutation analysis of Gaucher patients. Am J Med Genet. 1992 Feb 1;42(3):331–336. doi: 10.1002/ajmg.1320420315. [DOI] [PubMed] [Google Scholar]
  13. TUCHMAN L. R., SUNA H., CARR J. J. Elevation of serum acid phosphatase in Gaucher's disease. J Mt Sinai Hosp N Y. 1956 Mar-Apr;23(2):227–229. [PubMed] [Google Scholar]
  14. Van Weely S., Van Leeuwen M. B., Jansen I. D., De Bruijn M. A., Brouwer-Kelder E. M., Schram A. W., Sa Miranda M. C., Barranger J. A., Petersen E. M., Goldblatt J. Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochim Biophys Acta. 1991 Jun 5;1096(4):301–311. doi: 10.1016/0925-4439(91)90066-i. [DOI] [PubMed] [Google Scholar]
  15. Yang Y., Hamaguchi K. Hydrolysis of 4-methylumbelliferyl N-acetyl-chitotetraoside catalyzed by hen lysozyme. J Biochem. 1980 Sep;88(3):829–836. doi: 10.1093/oxfordjournals.jbchem.a133037. [DOI] [PubMed] [Google Scholar]
  16. Zimran A., Kay A., Gelbart T., Garver P., Thurston D., Saven A., Beutler E. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992 Nov;71(6):337–353. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES